Skip to content
MSCopilot
I am a Healthcare ProfessionalI am a PatientScientific References
Login Pro
I am a Healthcare ProfessionalI am a PatientScientific ReferencesLogin Pro
Back to home

Scientific References

The scientific evidence for MSCopilot® is organized by clinical study, with each study grouping its associated publications and communications and clearly distinguishing peer-reviewed articles from conference communications.

Clinical studies

MSCopilot® pivotal clinical validation study

Multicenter, randomized, crossover study comparing MSCopilot® to reference clinical tests (MSFC) in people with MS. The acceptability of the app in clinical practice was also assessed.

Completed studyRegistry: NCT03148938

Publications & communications

1
Peer-reviewed article

Maillart E, et al.

MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests

European Journal of Neurology. 2020;27(3):429-436

Core peer-reviewed validation reference. Multicenter, randomized, crossover study comparing MSCopilot® to standard MS tests (MSFC). AUC of 0.92 (vs 0.89 for MSFC), sensitivity of 81% and specificity of 82% for identification of patients with EDSS > 3.5. Assessment of reliability and reproducibility.

DOI: 10.1111/ene.14091PMID: 31538396PubMed
2
Peer-reviewed article

Tanoh IC, et al.

Exploring the relationship between MSCopilot, a multidimensional patient self-assessment digital solution, and the Expanded Disability Status Scale

Multiple Sclerosis and Related Disorders. 2021;55:103164

Main EDSS-alignment reference. Correlation of MSCopilot® scores with EDSS (r=0.65). AUC of 0.92 for discrimination of EDSS > 3.5 vs EDSS ≤3.5 patients. Characterization of disability dimensions: walking, dexterity, cognition and vision.

DOI: 10.1016/j.msard.2021.103164PMID: 34352512PubMed
3
Conference poster

Maillart E, et al.

MSCopilot®, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests. A randomized clinical trial

ECTRIMS 2019 / Multiple Sclerosis Journal supplement

Conference communication supporting the Maillart 2020 publication. Description of the multicenter, randomized, crossover design.

View
4
Conference abstract

Maillart E, et al.

Results of the MSCopilot Study

AAN 2019, P3.2-012

Conference communication documenting early scientific presentations of the pivotal validation study.

View
5
Conference abstract

Maillart E, et al.

Acceptability in clinical practice of MSCopilot, a smartphone application for digital self-assessment of patients living with multiple sclerosis

ECTRIMS 2018, P702

Majority of respondents favourable to the use of the app in MS care. Marked preference for digital tests over standard tests.

View

MS-DETECT — Early detection of MS progression

International, multicenter, prospective, longitudinal study evaluating MSCopilot® Detect in real-world at-home conditions for detecting disability worsening (target: 336 participants, >35 sites, 7 countries, 18–24 month follow-up).

Ongoing studyRegistry: NCT05816122

Publications & communications

6
Oral communication

Vermersch P, et al.

Correlation of real-world digital biomarkers with clinical standards, findings from the MS-DETECT study

EAN 2026, Genève (A-26-17831)

1-year longitudinal interim analysis. In 244 participants, MSCopilot® composite scores measured in-clinic (r=0.71) and at home (r=0.71–0.74; p<0.001) correlated with MSFC-4, and the correlation was maintained over time.

View
7
Conference poster

Graves JS, et al.

Concurrent Validity of MSCopilot® Digital Biomarkers in Real-world Settings Within the MS-DETECT Study

ACTRIMS Forum 2026, P173

Concurrent validity of digital biomarkers in real-world settings. Moderate-to-strong correlations with MSFC-4 components.

View
8
Conference poster

Vermersch P, et al.

MSCopilot® digital biomarkers obtained in a real-world setting correlated with their clinical counterparts in the MS-DETECT study

ECTRIMS 2025, P1583

Interim analysis: correlation of at-home MSCopilot® digital biomarkers with their MSFC-4 clinical counterparts.

View

MS-FLOWER — Integration of MSCopilot into routine clinical care

US multicenter, prospective pilot study (4 centers, 8 MS specialists, 62 patients; 6-month follow-up) evaluating the feasibility, usability and integration of MSCopilot® into routine clinical care.

Completed studyRegistry: NCT06922942

Publications & communications

9
Conference poster

Freeman L, et al.

MS-FLOWER, an Ongoing U.S. Multicenter Pilot Study to identify challenges to MSCopilot®'s integration into Multiple Sclerosis standard clinical care

EAN 2026, Genève — ePoster (EPO-0987)

Interim analysis of a feasibility pilot study (4 US centers, 8 specialists, 62 patients). After training, all healthcare providers felt confident introducing MSCopilot® (75% in 5 minutes or less), and all patients surveyed after inclusion found it easy to use.

View

Promotional claims should be supported by objective and verifiable data. Peer-reviewed articles are preferred over conference communications.

MSCopilot
CE

MSCopilot (DA100) is a class IIa digital medical device in the European Union, manufactured by Ad Scientiam in accordance with Regulation (EU) 2017/745. The device is CE marked based on a conformity assessment carried out by the notified body Kiwa Cermet Italia (CE 0476), applying from version 2.0 onwards.

In the United States, MSCopilot (DA100) is a class II digital medical device developed by Ad Scientiam, listed with the Food and Drug Administration (FDA) and commercialized in accordance with applicable regulatory requirements. The device is exempt from premarket notification requirements (510(k)).

FacebookLinkedInInstagram

Menu

  • Healthcare Professional
  • Patient

Legal

  • Legal Notice
  • Privacy Policy – Website

Help

  • Terms of Use
  • Privacy Policy
  • Instructions for Use
  • FAQ
  • Scientific References

Get in touch

Download the app

Download on the App StoreGet it on Google Play
Developed byAd Scientiam

MSCopilot® must be used only in accordance with its intended purpose, under the conditions and versions specified by the manufacturer, and in accordance with the applicable instructions for use. Do not use the device outside the indications, limitations, contraindications or technical conditions specified in the instructions or labeling.

Read the instructions for use carefully before use.  If in doubt about the use of the device, the results provided or your state of health, ask your doctor or any other qualified healthcare professional for advice. This device does not replace medical advice.

In accordance with applicable regulatory requirements, any serious incident, adverse effect or complaint related to the use of MSCopilot must be reported without delay to Ad Scientiam at the following address:

  • - For patients using the Application: contact@mscopilot.com
  • - For healthcare professionals using the Dashboard: contact.pro@mscopilot.com

Ad Scientiam, SAS au capital de 673 770 €, sis au 38 rue Dunois 75647 Paris CEDEX 13 France, RCS PARIS 795 083 336 All rights reserved | Website version 1.1.3 – updated on